Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A double-blind, cross-over comparison of Naprosyn (naproxen) 750 mg daily and Butacote (enteric-coated phenylbutazone) 300 mg daily was carried out in a multi-centre trial. Twenty-five patients, mostly male and under 40 years of age, were entered. After a 2-week period in which any existing anti-inflammatory drugs were tailed off, patients were entered into the trial and treated for 1 month with each drug. Patients were assessed at 4-weekly intervals. Both drugs significantly reduced morning stiffness. Morning pain and discomfort and wall-tragus distance were also significantly reduced by both drugs during the trial. Results of the Schober test showed improvement during both treatment periods. There were no overall statistically significant differences between the effects of the 2 drugs on objective parameters. However, overall subjective assessment of symptoms showed a greater improvement on Butacote. Treatment preferences by physician and subjective assessment by the patient both favoured Butacote but the difference between the 2 drugs was not statistically significant. Side effects were mostly of a minor nature. One patient had to discontinue the trial, due to indigestion while taking Butacote.
 ...
PMID:A comparative study of Butacote and Naprosyn in ankylosing spondylitis. 36 71

Two non-steroidal antirheumatic drugs, diclofenac (Voltaren) and naproxen (Proxen), were compared with respect to their analgesic effect and the observed improvement in joint mobility in two groups of patients, each consisting of 20 males with either cox-arthrosis or gonarthrosis. The duration of treatment was up to six months. The therapeutic response was assessed by the mean scores of spontaneous and exercise-induced pain, the clinical state of joints and painfree time of walking. Both drugs led to a persistent improvement in the condition of most patients, but the clinical impression would appear to point to a more marked analgesic effect of diclofenac. The daily maintenance dosage from the fourth week of treatment onwards was 75 mg diclofenac and 500 mg naproxen. Both drugs were generally well tolerated. Occasionally gastrointestinal side effects were observed (more frequently in the naproxen group). Laboratory controls were carried out periodically, but no evidence of organ toxicity or hemotoxic effects was found.
 ...
PMID:[Long-term comparative study: diclofenac (voltaren) and naproxen (proxen) in arthritis]. 62 55

A standard fixed dosing regimen (S) and a variable dosing regimen (VD) of naproxen for patients with knee and hip osteoarthritis were compared in a multicentre, open, controlled, parallel 8-week trial. The daily dose of naproxen (Naprosyn) in the S-group was 500-1000 mg, in VD maximum daily dose was 1000 mg. The number of patients entering the study was 396 (286 females). Mean (SD) age was 67 (10) and 67 (11) years in the S- and VD-groups respectively. The number of patients available for efficacy analyses, including the withdrawals, was 356. Efficacy measures included pain on movement, night pain, morning stiffness, a functional index and patient's and doctor's overall assessments. Similar improvement was seen in both groups. The number of patients withdrawn due to adverse reactions in S and VD was 35 and 23 respectively (p less than 0.05). Group differences in drug consumption were highly significant (p less than 0.01) with a 20-30% lower consumption in the VD-group. Thus, similar efficacy and possibly better tolerance was obtained with a lower drug consumption by a variable dosing regimen compared to a fixed regimen.
 ...
PMID:Improved cost-effectiveness ratio with a patient self-adjusted naproxen dosing regimen in osteoarthritis treatment. 192 16

Twenty-one women with intrauterine contraceptive devices (IUCD) and severe dysmenorrhea were studied. All the women who participated in the study had primary dysmenorrhea of varying intensities. The insertion of IUCD increased the intensity of dysmenorrheic pain. The effect of naproxen (Naprosyn) on pain alleviation was studied in a double-blind cross-over trial using naproxen and placebo. The effect of naproxen was significantly better than that of placebo (P less than 0.01). No severe side effects occurred during the treatment. There was no difference in the duration and amount of the menstrual blood flow during naproxen treatment compared to placebo according to the women's own judgement.
 ...
PMID:Dysmenorrhea in women with intrauterine contraceptive device. Treatment with a prostaglandin synthetase inhibitor, naproxen. 613 91

Altogether 105 rheumatic patients, 35 in each of three groups, took part in a double-blind parallel study comparing naproxen (Naprosyn, Syntex) 500 mg suppositories with oxyphenbutazone (Tanderil, Geigy) 250 mg suppositories and placebo in postoperative pain and swelling after joint surgery. Medication was administered twice daily for 3 1/2 days, starting the night before operation. Ketogan (Ketobemidonhydrochloride, 3 dimethylamino-1-diphenylbuten-(1)-hydrochloride) injections and Paralgin Forte (Paracetamol, codein phosphate) tablets were allowed as escape medication. Each day clinical assessments including pain-score, oedema-score and circumference of operated joint were performed and amount of escape medication recorded. A physical test was performed on day seven after operation. No statistically significant difference between groups was observed for most parameters. In general the tendency for all parameters seems to favour naproxen. For pain-score the difference was significant (p = 0.02) in arthrodesis/arthroplasty patients day 1 and for need for Ketogan injections (p less than 0.001) in all patients day 0. Only two side effects were recorded during the study. In the present study no significant difference between the groups could be observed for most parameters measured. The tendency seems to favour naproxen, but a larger number of patients will be needed to investigate whether this observation is of significance.
 ...
PMID:Naproxen suppositories in postoperative pain and swelling after joint surgery. A comparative, double-blind study. 637 84

Three therapeutic regimens using nonsteroidal antirheumatic drugs in the treatment of rheumatoid arthritis were compared in an open long-term cross-over trials. Voltaren 100 mg suppositories or Naprosyn 500 mg suppositories were introduced every evening at bed-time, and Naprosyn tablets were administered twice in a day, in the morning and at night. Each drug was administered for one month and every patient was treated with all three drugs in succession. The individual sequence was determined by randomization. The assessment included nine objective and subjective criteria and after the termination of the trial each patient named his preferred sequence of drugs. All three drugs proved effective. The results of our investigations showed that nonsteroidal antirheumatic drugs in the form of suppositories were more effective in the treatment of rheumatoid arthritis. They exerted a more beneficial effect on morning stiffness and on pain than tablets of the same drug. The treatment was most effective as late as in the third month of the therapy, regardless of the substance which was administered as the third drug. This confirmed our experience of the advantage of alternate administration of various nonsteroidal antirheumatic drugs. A series of subjective and objective criteria, as well as the preference expressed by the patients spoke in favour of Voltaren suppositories, which was obviously due to the fact that Naprosyn was ineffective in about 20 per cent of the patients.
 ...
PMID:Comparison of three therapeutic regimens using nonsteroidal antirheumatic drugs in patients with rheumatoid arthritis. 729 22

40 patients with degenerative joint diseases were treated with a new application form of naproxen (Proxen 500 film-coated tablets). The patients received one tablet daily in the evening for a period of 4 weeks. The therapeutic efficacy was demonstrated clinically on swelling of the joints, reduction of mobility, pressure pain, muscular stiffness and by improvement of pain symptoms: pain during day and night, pain at rest, movement pain. During therapy 75% of the cases showed marked improvement of the subjective and objective symptoms. The once daily application in the evening did not only influence favourable nocturnal and rest pain, but also reduced diurnal and movement pain significantly. In accordance with these findings 23 hours after application in the evening nearly constant serum levels of naproxen were found for the whole duration of treatment. The fast release of the active substance from the film-coated tablets leads to a rapid onset of the analgesic activity.
 ...
PMID:[Therapy of degenerative joint diseases of a rheumatic nature. Effectiveness of naproxen at a daily dosage of 500 mg]. 746 54

Osteoarthritis is the most common joint disease and the second highest ranking cause of disability in the US. Osteoarthritis commonly affects the hands, wrists, spine, knees, and feet. One of the mainstays of treatment for osteoarthritis is the use of nonsteroidal anti-inflammatory drugs. While there have been controlled comparison studies of the various nonsteroidal anti-inflammatory drugs, these have been limited to osteoarthritis of the hands, spine, and hip. This study was a randomized, double-blind, parallel study of 8 weeks' duration comparing piroxicam (Feldene, 20 mg daily) to naproxen (Naprosyn, 1,000 mg daily) in the treatment of osteoarthritis of the foot in 45 patients. Both groups experienced significant pain relief and improvement of mobility.
 ...
PMID:Comparison of piroxicam and naproxen in osteoarthritis of the foot. 806 97

Dysmenorrhea is a widespread phenomenon, affecting mainly young nulliparous women, often inducing difficulties in study or in work. Its pathogenesis involves a release of local vasoconstrictors like Prostaglandins and Leukotrienes. Modern therapy is based firstly on the administration of prostaglandin-Synthetase Inhibitors or Contraceptive Pills, with the aim of reducing the menstrual excess of pain inducing substances. In order to achieve more efficacy, on the basis of the already proven effectiveness of the Non Steroid Anti-Inflammatory Drugs (NSAID)s in this field, we recently set out to prevent dysmenorrhea in a double-blind randomized study with Meclofenamate Sorium and Naproxen Sodium. Through the observation of the drop in Basal Body Temperature which usually precedes menstrual flow, we were able to instruct our patients in the earlier recognition of impending menstrual onset, leading to earlier prevention of Prostaglandin and Leukotriene release. Meclofenamate Sodium in particular led to considerable pain reduction, with very good patient compliance and without significant complications, probably of its additional receptor effect.
 ...
PMID:An attempt at real prophylaxis of primary dysmenorrhea: comparison between meclofenamate sodium and naproxen sodium. 833 Apr 29

A double-blind, randomized study compared the efficacy and safety of a controlled-release naproxen sodium formulation (Naprelan, Wyeth-Ayerst Laboratories, Philadelphia, Pennsylvania) 1,000 mg once daily; a conventional naproxen formulation (Naprosyn, Syntex Laboratories, Inc., Palo Alto, California) 500 mg BID; and placebo given for 12 weeks to 348 patients with rheumatoid arthritis (RA). This was followed by an open-label study to evaluate the safety of naprelan 1,000 mg once daily for an additional 9 months. In the double-blind phase of this study, the safety and efficacy of Naprelan 1,000 mg once daily were compared with those of Naprosyn 500 mg twice daily and placebo in 348 patients with RA. At the end of 12 weeks of treatment, Naprelan and Naprosyn were numerically superior to placebo in 3 of the 4 primary efficacy variables--physician's global assessment, patient's global assessment, and number of painful joints. Differences between Naprelan and placebo reached statistical significance for the patient's global assessment at Week 12 (Visit 7). Significantly more Naprosyn- than placebo-treated patients had at least 1 severe digestive system adverse event (AE); 1 drug-related AE; or 1 drug-related, digestive-system AE. There was no statistically significant difference in the number of AEs experienced by Naprelan-treated patients compared with those who received placebo. A total of 240 patients enrolled in the Naprelan open-label phase. As would be expected, patients initially treated with placebo showed significant improvement after starting Naprelan. Those initially receiving Naprelan or Naprosyn also maintained their improvement. The AE profile with Naprelan was similar to that reported in the double-blind phase. It was concluded that Naprelan 1,000 mg once daily was as effective as Naprosyn 500 mg BID in the treatment of RA and was particularly effective in relieving pain later in the day. The controlled-release formulation may also offer safety benefits.
 ...
PMID:Clinical efficacy and safety of Naprelan versus Naprosyn in the treatment of rheumatoid arthritis. 888 14


1 2 Next >>